OPTIMIZATION OF TRANSDERMAL NANOPARTICLES FOR INSULIN DELIVERY

Sohan Lal Gurjar*, Prof. Dr. Pankaj Kumar Sharma, Prof. Dr. Jaya Sharma, Prof. Dr. Rekha Kanwar, Dr. Monika Jain

ABSTRACT

Diabetes mellitus is one of the most prevalent chronic metabolic disorders worldwide and is characterized by persistent hyperglycemia resulting from impaired insulin secretion, insulin resistance, or both. Despite significant advancements in diabetes management, the conventional subcutaneous administration of insulin remains associated with several limitations, including pain, poor patient compliance, risk of infection, local tissue irritation, and fluctuating plasma insulin levels. These challenges have prompted extensive research into alternative, patient-friendly drug delivery systems. Among these, transdermal drug delivery has emerged as a promising non-invasive approach due to its ability to provide sustained drug release, improve patient adherence, and reduce systemic side effects. However, the large molecular size, hydrophilic nature, and enzymatic instability of insulin significantly restrict its permeation through the stratum corneum, the primary barrier of the skin. Nanoparticle-based delivery systems have demonstrated considerable potential in overcoming these physiological barriers by enhancing drug stability, facilitating skin penetration, and enabling controlled insulin release. The present study focuses on the optimization of transdermal nanoparticles for insulin delivery with the objective of developing a stable, efficient, and biocompatible carrier system capable of improving insulin permeation across the skin. Polymeric or lipid-based nanoparticles are formulated using suitable preparation techniques, and critical formulation variables such as polymer concentration, surfactant concentration, drug-to-polymer ratio, and process parameters are systematically optimized to achieve desirable physicochemical characteristics. The prepared nanoparticles are evaluated for particle size, polydispersity index, zeta potential, drug loading capacity, encapsulation efficiency, morphology, in vitro drug release, and stability. Furthermore, the optimized nanoparticle formulation is incorporated into a transdermal delivery system and assessed for skin permeation, drug retention, biocompatibility, and pharmacodynamic performance using suitable in vitro and ex vivo models. Optimization through statistical design approaches ensures the identification of the most influential formulation variables while minimizing experimental variability. The optimized transdermal nanoparticle formulation is expected to exhibit high encapsulation efficiency, nanoscale particle size, sustained insulin release, enhanced skin permeation, and improved physicochemical stability without compromising the biological activity of insulin. Such a delivery system may effectively maintain therapeutic plasma insulin concentrations for prolonged periods while minimizing the frequency of administration and improving patient comfort. Additionally, the incorporation of nanoparticles into transdermal systems may protect insulin from enzymatic degradation and facilitate controlled release, thereby enhancing therapeutic efficacy. In conclusion, the optimization of transdermal nanoparticles represents a promising strategy for the non-invasive delivery of insulin and has the potential to overcome the limitations associated with conventional insulin therapy. The successful development of an optimized nanoparticle-based transdermal formulation may contribute significantly to improving glycemic control, enhancing patient compliance, reducing treatment-associated complications, and advancing the field of nanotechnology-based drug delivery systems for diabetes management.

Keywords: Diabetes mellitus, insulin delivery, transdermal drug delivery, nanoparticles, formulation optimization, controlled drug release, and skin permeation.